Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers August 18, 2017
Pharmacy Choice - News - Generic Drugs - August 18, 2017

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

7/19/17 - CADILA'S NEW MANAGING DIRECTOR SHRAVIL PATEL AIMS TO DOUBLE REVENUES IN 5 YEARS
Cadila Healthcare Ltd is targeting to double its revenues by 2022, says Shravil Patel, managing director at Cadila Healthcare. Its revenues were at Rs9, 600 crore in 2016-2017. The company will focus on developing innovative drugs and biosimilars, besides betting more on diabetes drug saroglitazar which is in phase two trial in the US. It is expect
7/19/17 - Investigators from George Washington University Target Biologics (A Survey Assessment of US Dermatologists' Perception of Biosimilars)
By a News Reporter-Staff News Editor at Biotech Week Research findings on Biotechnology- Biologics are discussed in a new report. According to news reporting originating from Washington, District of Columbia, by NewsRx correspondents, research stated, "Biologics have transformed the treatment of psoriasis and psoriatic arthritis, but at a signifi
7/19/17 - Israeli pharmaceutical giant Teva faces up to $2.19 billion for pay for delay pharma agreement [Arab Times (Kuwait)]
The European Commission has sent a statement of objections and thus initiated antitrust proceedings against Israeli pharmaceutical company Teva for breaching EU rules. They now face a fine of up to 10% of their $21.9 billion in annual revenue, meaning that Teva could end up being fined up to $2.19 billion if the Commissions Competition authorities
7/19/17 - Reps. Marino and Cicilline Applaud FDA's Public Meeting on Generic Drug Pricing
Tom Marino, R- Pa., issued the following news release:. Today, the U.S. Food and Drug Administration held a public meeting to solicit input in areas where the FDA's rules are being used in ways that create obstacles and delays. On April 27, 2017, Representatives Tom Marino and David N. Cicilline, Chairman and Ranking Member, respectively, of the Ho
7/19/17 - Rutledge Files Suit Against Drug Makers for Anti-Trust Violations
Arkansas Attorney General Leslie Rutledge issued the following news release:. Arkansas Attorney General Leslie Rutledge has joined with three other states and the District of Columbia in filing a lawsuit in federal court alleging that six generic drug makers, including Aurobindo Pharma USA Inc., Citron Pharma LLC, Heritage Pharmaceuticals Inc., May
7/19/17 - Sen. Alexander: Americans Want to Know Who Pays for Prescription Drugs and Where That Money Goes
United States Senator Lamar Alexander today chaired a bipartisan Senate health committee hearing to examine the path a FDA- approved prescription drug takes from the manufacturer to patient, and how this path affects what the patient pays, saying "Americans want to know who pays for prescription drugs and where that money goes." Alexander continued
7/18/17 - Alembic Pharma gets USFDA nod for Olmesartan Medoxomil and Amlodipine tablets [India Infoline News Service]
Alembic Pharmaceuticals Limited announced that the company has received approval from the USFDA for its abbreviated new drug application for Olmesartan Medoxomil and Amlodipine tablets. Alembic Pharmaceuticals Limit ed announced that the company has received approval from the USFDA for its abbreviated new drug application for Olmesartan Medoxomil..
7/18/17 - Congressmen Marino and Cicilline Applaud FDA's Public Meeting on Generic Drug Pricing
Washington, D.C. Today, the U.S. Food and Drug Administration held a public meeting to solicit input in areas where the FDA's rules are being used in ways that create obstacles and delays. Commissioner Gottlieb commented last week that the FDA has seen problems with branded pharmaceutical companies using the Risk Evaluation and Mitigation Strateg
7/18/17 - EU charges Teva over delaying cheap sleep drug [Syrian Arab News Agency]
European Union regulators on Monday filed antitrust charges against Israeli drug-maker Teva for colluding to delay a cheaper generic version of modafinil, a blockbuster sleep drug. The EU, under the stewardship of Competition Commissioner Margrethe Vestager, said Teva had agreed to the delay in return for "a substantial transfer of value from Cepha
7/18/17 - EU Pushes Teva Pharmaceutical Industries Ltd (ADR) ADR (NYSE:TEVA) Over Pay-For-Delay Drug Dealing
Teva Pharmaceutical Industries Ltd (ADR) ADR (NYSE:TEVA) is facing serious charges after EU antitrust regulators went to court. The body on Monday accused the top provider of conniving with Cephalon in a bid to put in place delays on the sale of a cheaper generic version of a sleep disorder drug. People familiar with the [?] The post EU Pushes Te
7/18/17 - European Commission Sends Statement of Objections to Teva on Pay for Delay Pharma Agreement
The European Commission has informed pharmaceutical company Teva of its preliminary view that an agreement concluded with Cephalon was in breach of European Union (EU) antitrust rules. Under the agreement, Teva committed not to market a cheaper generic version of Cephalon's drug for sleep disorders, modafinil.
7/18/17 - FDA Moves to Enable Competition
In remarks released by the FDA Tuesday ahead of a public meeting on competition for generic drugs Gottlieb outlined some additional ways the regulator plans to speed those cheaper medicines to market. His remarks make mention of generic drug makers being able to obtain letters from the FDA permitting branded companies to sell them their drug fo
7/18/17 - Glenmark Pharmaceuticals Enters Exclusive Agreement with Cyndea Pharma S.L. for Generic Soft-Gelatin Capsule Drug Products
Accessing this formulation and manufacturing technology with our strategic partner Cyndea will support Glenmark's continued mission of providing important and cost-effective generic medicines to patients. " Under this agreement, Glenmark receives exclusive rights to the United States and Canada markets for these soft-gelatin formulations in...
7/18/17 - Global Adalimumab Biosimilar Market 2017 - AET BioTech, Amgen, Boehringer Ingelheim, Coherus Biosciences
This report studies Adalimumab Biosimilar in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 202...
7/18/17 - Global Biosimilar Market 2017- Astra Zeneca Plc, Amgen Inc and Biocon Ltd
Pune, India 07/18/2017 The valuation of Global Biosimilar Market is USD 3 billion in 2016. The Biosimilar Market report encompasses forecasts, analysis and discussion of trade facts, Biosimilar market size, evaluation of market share and profiles of the famous Biosimilar industry players on a global and regional level.Do Inquiry Before Access
7/18/17 - Hospira, Inc. et al.; Withdrawal of Approval of 44 New Drug Applications and 158 Abbreviated New Drug Applications; Correction
SUMMARY: The Food and Drug Administration is correcting a notice that appeared in the Federal Register of October 4, 2016. The document inadvertently announced withdrawal of approval for the following two ANDAs: ANDA 074123 for Pindolol Tablets, held by G&W Laboratories, Inc., 111 Coolidge St., South Plainfield, NJ 07080; and ANDA 080828 for Hydroc
7/18/17 - Morgans rates IDT as Downgrade to Reduce from Add
Dr Paul MacLeman joined IDT in 2013 to turn around the business and acquired a portfolio of 23 generic drugs planned for manufacture and US distribution. Little progress left investors frustrated and now MacLeman has resigned. His resignation leaves the company's generic drug strategy under a cloud, the broker suggests.
7/18/17 - Morrisey joins lawsuit against pharmaceutical companies [Times West Virginian, Fairmont]
July 18 FAIRMONT West Virginia Attorney General Patrick Morrisey announced Monday that he is joining a multistate lawsuit alleging six pharmaceutical companies colluded to fix prices of generic drugs. The lawsuit, filed along with attorneys general from Arkansas, the District of Columbia, Missouri and New Mexico, said that the companies had a "
7/18/17 - New HIV drug for Nigeria [Sun, The (Nigeria)]
it is heartwarming that a generic version of the most advanced drug for the treatment of Human Immuno-deficiency Virus is to be introduced in Nigeria before the end of the year. With this development, the drug, Dolutegravir which is used in many advanced countries, but not in Africa because of the high cost, will be introduced in Nigeria and Uganda
7/18/17 - Sartorius Stedim Biotech introduces complete range of chemistry testing services [All Iraq News Agency (AIN)]
Sartorius Stedim Biotech, a leading international supplier for the biopharmaceutical industry, announced the launch of a full range of chemistry testing services. Offered by its subsidiary Sartorius Stedim BioOutsource, they characterize the physicochemical properties and structural attributes of therapeutic monoclonal antibodies.
7/18/17 - Today's Research Reports on Stocks to Watch: Valeant Pharmaceuticals and Impax Laboratories
NEW YORK, NY/ ACCESSWIRE/ July 18, 2017/ Valeant Pharmaceuticals has sold its Obagi skin care unit to throw more money at a $5 billion debt it wants to reduce by February of 2018. Impax Laboratories saw some big gains after announcing yesterday morning that the FDA has approved a generic version of Concerta. Valeant Pharmaceuticals International, I
7/18/17 - W.Va. joins four others in lawsuit [The Dominion Post, Morgantown, W.Va.]
July 18 West Virginia has joined with four other plaintiffs to sue Mylan Pharmaceutics and five other generic drug makers, alleging antitrust violations involving an antibiotic and an oral diabetes medication. The other four plaintiffs are Arkansas, the District of Columba, Missouri and New Mexico. The other defendants are Aurobindo Pharma USA, o
7/17/17 - Generic drug deal to save Quebec more than $300 million yearly: Barrette
MONTREAL The Quebec government says it will save more than $300 million yearly on generic medications after reaching a deal with the association representing Canada's generic pharmaceutical companies.
7/17/17 - Impax Announces FDA Approval of its AB Rated Generic Concerta (Methylphenidate Hydrochloride) Extended-Release Tablets CII
Impax Laboratories, Inc., a specialty pharmaceutical company, today announced it has received an AB therapeutic equivalent rating and final U.S. Food and Drug Administration approval on its Abbreviated New Drug Application for a generic version of Concerta Extended-Release tablets USP CII, 18, 27, 36 and 54 mg. "Approval of our AB-rated gener
7/17/17 - Life and Health Insurance Industry Supports Lower Pricing for Generic Drugs
-The life and health insurance industry in Quebec welcomes Health Minister Gatan Barrette's announcement that an agreement has been reached with generic drug manufacturers to significantly lower generic drug prices. "The details of the agreement are still confidential, but we are very hopeful that we can all work together the government, pharm
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415